| 5.7 0.32 (5.95%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.48 | 1-year : | 8.31 |
| Resists | First : | 6.4 | Second : | 7.11 |
| Pivot price | 6.42 |
|||
| Supports | First : | 5.25 | Second : | 4.37 |
| MAs | MA(5) : | 6.09 |
MA(20) : | 6.36 |
| MA(100) : | 5.54  |
MA(250) : | 4.69 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 18.7 |
D(3) : | 32.1 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 7.3 | Low : | 2.33 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TSHA ] has closed above bottom band by 5.1%. Bollinger Bands are 24.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.86 - 5.9 | 5.9 - 5.93 |
| Low: | 5.23 - 5.27 | 5.27 - 5.31 |
| Close: | 5.64 - 5.7 | 5.7 - 5.76 |
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Mon, 13 Jul 2026
Taysha Gene Therapies (TSHA) Experiences Significant Decline - GuruFocus
Sun, 12 Jul 2026
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run - The Motley Fool
Fri, 10 Jul 2026
Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha G - GuruFocus
Fri, 10 Jul 2026
Taysha Gene Therapies president sells $1.25m in stock - Investing.com
Fri, 10 Jul 2026
Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan - Stock Titan
Fri, 10 Jul 2026
Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 287 (M) |
| Held by Insiders | 2.0595e+008 (%) |
| Held by Institutions | 9.5 (%) |
| Shares Short | 36,010 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3141e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 774.3 % |
| Return on Equity (ttm) | -37.8 % |
| Qtrly Rev. Growth | 7.47e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -84.6 |
| EBITDA (p.s.) | 6.49565e+006 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 8.85 |
| Dividend | 0 |
| Forward Dividend | 4.14e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|